On July 14, the US biotech company Moderna announced that it would start the final phase 3 human trials of its experimental coronavirus vaccine, mRNA vaccine, on July 27.
The phase 3 trial will evaluate how well the vaccine can protect humans from the SARS-CoV-2 virus that causes COVID-19.
With this, Moderna became the first in the US to announce an estimated start date for the phase 3 study.
On Tuesday, the Moderna researches reported that the experimental COVID-19 vaccine boosted the immune system in the first 45 volunteers.
According to the researchers, the volunteers developed neutralizing antibodies in their bloodstream, the molecules key to blocking infection, at levels comparable to those found in people who survived COVID-19.
“Vaccine shown to provide an immune boost in 45 volunteers. No matter how you slice this, this is good news,” said Dr. Anthony Fauci, the US Government’s top infectious disease expert.
Now, Moderna will start a 30,000-person study to prove if the vaccine shots are strong enough to protect against the coronavirus.
Likewise, nearly two dozen possible Covid-19 vaccines are in various stages of testing across the world. Researchers from China and Britain’s Oxford University also are entering the final testing stages.
So far, the coronavirus pandemic has infected 13,464,663 people worldwide and claimed 581,394 lives. Currently, there are 5,028,071 active cases and 7,855,198 recovery cases.
Stay Tuned to Nepali Sanasar for Latest COVID-19 Updates!
After drawing huge criticism from several quarters and nation-wide outcry, the Foreign Ministry has clarified that…Read more